(Q33217865)

24 July 2017

1 reference

title

Chemotherapy- and radiotherapy-induced oral mucositis: review of preventive strategies and treatment (English)

1 reference

adaptive radiation therapy

24 July 2017

main subject

0 references

1 reference

1 reference

Claire E Saadeh

1

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

24 July 2017

1 reference

24 July 2017

volume

25

1 reference

24 July 2017

issue

4

1 reference

24 July 2017

page(s)

540-554

1 reference

Oral mucositis: time for more studies

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Risk factors for chemotherapy-induced oral mucositis: dental appliances, oral hygiene, previous oral lesions, and history of smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

The PRO-SELF Mouth Aware program: an effective approach for reducing chemotherapy-induced mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Radiochemotherapy with amifostine cytoprotection for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Prevention of chemotherapy and radiation toxicity with glutamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Effect of oral glutamine supplementation during bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Acute mucositis in the stimulated oral mucosa of patients during radiotherapy for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Systemic absorption of lidocaine after topical application for the treatment of oral mucositis in bone marrow transplantation patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Lidocaine toxicity during frequent viscous lidocaine use for painful tongue ulcer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Sucralfate for radiation mucositis: results of a double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt & soda mouthwashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Randomized Phase I Trial of Recombinant Human Keratinocyte Growth Factor Plus Chemotherapy: Potential Role as Mucosal Protectant

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Palifermin for oral mucositis after intensive therapy for hematologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.4.540.61035

10.1592/PHCO.25.4.540.61035

21 January 2018

Identifiers

DOI

1 reference

24 July 2017

1 reference